Pharming Group (PHAR) Competitor Comparison
We are evaluating the key criteria listed to compare Pharming Group (PHAR) against its competitors in the Biotechnology industry.
Market Capitalization
143 / 368Gross Profits
34 / 278Total Revenue
55 / 300EBITDA
73 / 337Free Cashflow
32 / 352Quick Ratio
244 / 357Earnings per Share
63 / 359Dividend yield
0 / 6Total Cash
157 / 358Performance 3 years
101 / 368Performance 5 years
186 / 368Performance 10 years
159 / 368Linearity 3 years
9 / 368Linearity 5 years
122 / 368Linearity 10 years
93 / 368Total Rank
226 / 368Dividend Rank
38 / 368Valuation Rank
135 / 368Piotroski Rank
33 / 368Muliplier Rank
177 / 368Free Cashflow - PHAR ranking 32 / 352
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.